1. Home
  2. PII vs LEGN Comparison

PII vs LEGN Comparison

Compare PII & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polaris Inc.

PII

Polaris Inc.

HOLD

Current Price

$52.35

Market Cap

3.3B

ML Signal

HOLD

LEGN

Legend Biotech Corporation

HOLD

Current Price

$18.88

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PII
LEGN
Founded
1954
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.6B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PII
LEGN
Price
$52.35
$18.88
Analyst Decision
Hold
Strong Buy
Analyst Count
11
12
Target Price
★ $62.27
$61.33
AVG Volume (30 Days)
715.6K
★ 1.8M
Earning Date
04-27-2026
05-12-2026
Dividend Yield
★ 4.05%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $7,152,000,000.00
N/A
Revenue This Year
$1.20
$42.68
Revenue Next Year
$4.51
$30.52
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$47.14
$16.24
52 Week High
$77.98
$37.50

Technical Indicators

Market Signals
Indicator
PII
LEGN
Relative Strength Index (RSI) 27.71 45.35
Support Level $52.22 $17.81
Resistance Level $74.00 $19.36
Average True Range (ATR) 1.94 0.80
MACD -0.14 0.15
Stochastic Oscillator 9.32 66.89

Price Performance

Historical Comparison
PII
LEGN

About PII Polaris Inc.

Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational, utility, military, and commercial purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: